Asset Details
Do you wish to reserve the book?
Identification of a novel somatic mutation of POU6F2 by whole‐genome sequencing in prolactinoma
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Identification of a novel somatic mutation of POU6F2 by whole‐genome sequencing in prolactinoma
Do you wish to request the book?
Identification of a novel somatic mutation of POU6F2 by whole‐genome sequencing in prolactinoma
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Identification of a novel somatic mutation of POU6F2 by whole‐genome sequencing in prolactinoma
2019
Overview
Background Pituitary adenomas (PAs) are one of the most common intracranial tumors; approximately half of PAs are prolactin (PRL)‐secreting PAs (prolactinomas). The genetic alterations prevalent in prolactinomas are unknown. Methods Here, we present a patient with an extremely aggressive and giant prolactinoma accompanied by serious destruction of the surrounding bone mass. This patient exhibited resistance to dopaminergic drugs. Through whole‐genome sequencing, we identified two novel somatic mutations in the POU6F2 gene (NM_001166018.2: c. 839 C>T; NM_001166018.2: c. 875A>G). Results This report is the first to identify these somatic mutations in the POU6F2 gene in a prolactinoma. We found that these two mutations obviously decreased the expression level of POU6F2. Inhibition of POU6F2 activity increased the cell proliferation and PRL secretion in rat pituitary cells, but proliferation and PRL secretion were decreased in cells with POU6F2 overexpression. Conclusions POU6F2 might play a crucial role in the development of prolactinomas and may be a promising target for developing new therapies against prolactinomas. It is the first report of somatic mutation in POU6F2 gene in a prolactinoma. We found that these two mutations obviously decreased the expression level of POU6F2. Inhibition of POU6F2 activity increased the cell proliferation and prolactin (PRL) secretion in rat pituitary cells, the cell proliferation and secretion of PRL were decreased when POU6F2 overexpression was achieved.
Publisher
John Wiley & Sons, Inc,John Wiley and Sons Inc,Wiley
Subject
/ Adult
/ Animals
/ Cloning
/ DNA
/ Gene Expression Regulation, Neoplastic
/ Genomes
/ Humans
/ Male
/ Mutation
/ NMR
/ Original
/ Pituitary Neoplasms - genetics
/ Plasmids
/ POU Domain Factors - genetics
/ POU6F2
/ Proteins
/ Rats
/ Studies
/ Tumors
